Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.50 |
| ▸ | RAF1 | P04049 | 8/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545586 | 0.93 | BRAF (0.49) | BRAFRAF1CNR2KDRMTNR1A | |
| SCHEMBL545627 | 0.92 | BRAF (0.48) | BRAFRAF1CNR2KDRMTNR1A | |
| SCHEMBL545649 | 0.91 | CNR2 (0.50) | BRAFRAF1CNR2KDRMTNR1A | |
| SCHEMBL545759 | 0.91 | CNR2 (0.50) | BRAFRAF1CNR2KDRMTNR1A | |
| SCHEMBL545496 | 0.90 | BRAF (0.49) | BRAFRAF1KDRMTNR1AMTNR1B | |
| SCHEMBL545787 | 0.89 | BRAF (0.46) | BRAFRAF1CNR2KDRMTNR1A | |
| SCHEMBL546007 | 0.89 | BRAF (0.51) | BRAFRAF1KDRMTNR1AMTNR1B | |
| SCHEMBL546005 | 0.89 | BRAF (0.53) | BRAFRAF1KDRMTNR1AMTNR1B | |
| SCHEMBL545680 | 0.89 | BRAF (0.51) | BRAFRAF1KDRMTNR1AMTNR1B | |
| SCHEMBL545500 | 0.89 | BRAF (0.57) | BRAFRAF1KDRMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885RAF1 198/4885CNR2 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.